tiprankstipranks
Advertisement
Advertisement
Oppenheimer downgrades Legend Biotech to Perform on CEO/competition overhangs
PremiumThe FlyOppenheimer downgrades Legend Biotech to Perform on CEO/competition overhangs
7d ago
Legend Biotech price target raised to $49 from $48 at Morgan Stanley
Premium
The Fly
Legend Biotech price target raised to $49 from $48 at Morgan Stanley
7d ago
Okta upgraded, Gap downgraded: Wall Street’s top analyst calls
Premium
The Fly
Okta upgraded, Gap downgraded: Wall Street’s top analyst calls
7d ago
Buy Rating Reiterated as Strong CARVYKTI Momentum and Attractive Valuation Support Unchanged $65 Price Target
PremiumRatingsBuy Rating Reiterated as Strong CARVYKTI Momentum and Attractive Valuation Support Unchanged $65 Price Target
27d ago
Legend Biotech falls -15.1%
Premium
The Fly
Legend Biotech falls -15.1%
27d ago
Legend Biotech falls -12.5%
Premium
The Fly
Legend Biotech falls -12.5%
28d ago
Legend Biotech resumed with a Neutral at JPMorgan
PremiumThe FlyLegend Biotech resumed with a Neutral at JPMorgan
1M ago
Legend Biotech price target lowered to $63 from $64 at RBC Capital
Premium
The Fly
Legend Biotech price target lowered to $63 from $64 at RBC Capital
2M ago
Legend Biotech Prices $226 Million ADS Offering to Bolster Cell Therapy Expansion
Premium
Company Announcements
Legend Biotech Prices $226 Million ADS Offering to Bolster Cell Therapy Expansion
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100